Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Engineered
B cells
as medicines

Harnessing the immune system to
defeat cancer with tumor-selective
immunotherapies (NASDAQ: XLO)

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Preventing axonal degeneration in
patients with neurological diseases
Sold to Lilly (NYSE: LLY) Oct 2020

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Broadening the reach and
impact of precision medicine
to more people with cancer

Breakthrough therapies for neuro-
logical & psychiatric conditions
– Sold to Novartis Dec 2020

Rapidly developing new cancer
treatments for people of all ages
– IPO Jun 2021 (NASDAQ: DAWN)

Patient-directed oncology therapies
across immune and cancer cell pathways
IPO Mar 2021 (NASDAQ: IKNA)

Leading the
next frontier in
RNA therapeutics

Bispecific antibodies
to improve the treatment
of serious diseases

Pioneering transformative new
biotherapeutics for patients
(NASDAQ: SYBX)

Advancing novel therapies for people
with rare cardiopulmonary disease
– IPO Jun 2021 (NASDAQ: AVTE)

Pioneering targeted therapies
for serious muscle diseases –
IPO Sep 2020 (NASDAQ: DYN)

Building
the future of
gene therapy

Next generation ocular gene
therapies for vision restoration
and vision preservation

Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

New class of
regulated cell and
gene therapies

Advancing medicines for
allergy and inflammation
IPO Sep 2022 (NASDAQ: THRD)

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Precision therapeutics for
genetically-defined dry AMD
(NASDAQ: GMTX) Jan 2021

Discovering precision
covalent medicines for
immune diseases

Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019

Discovering and developing
safe, effective, and highly
targeted radiopharmaceuticals

Applying new insights in
hepcidin biology to
treat hematologic diseases

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Harnessing the power of microglia to
transform treatments for neuro-
degenerative diseases (NASDAQ: VIGL)

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

First-in-class RNA therapies
for severe genetic diseases
IPO Jun 2018 (NASDAQ: TBIO)

Scalable, re-dosable, non-viral
gene therapy for genetic diseases
IPO Jun 2020 (NASDAQ: GBIO)

Breakthrough computer-aided
drug design
for transformative medicines

Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Precision therapeutics
for genetically defined
diseases

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Cell and gene therapies
for rare diseases
IPO Jun 2018 (NASDAQ: AVRO)

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Targeting regulators of
innate and adaptive immunity
to restore immune homeostasis

Transformative treatments for
people with obesity and other
cardiometabolic diseases

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

ADC specialist
for solid
cancers

Target-first, rational
molecular glue
drug discovery platform

Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Developing highly effective
and differentiated treatments
for cystic fibrosis

Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)

Restoring ABC transporter
function for patients with
serious genetic diseases

Developing treatments for
complex rare diseases
(NASDAQ: LRMR)

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Reprogramming RNA processing
to address underlying
drivers of disease

Targeting progranulin and
lysosomal biology to treat
neurodegenerative diseases

Novel therapeutics
targeting
diseases of aging

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Harnessing the power of the epigenome to develop precision genomic therapeutics

Discovering new medicines
for severe
neurodegenerative diseases

Novel therapeutics
for severe
respiratory diseases